Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...

Boehringer Ingelheim Pharmaceuticals Inc. has appointed Brian Hilberdink as President, U.S. Human Pharma.

The use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...

In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.

The FDA has granted Priority Review to Boehringer Ingelheim's new drug application for its non-small cell lung cancer therapy ...

The U.S. Food and Drug Administration (FDA) has granted Priority Review to Boehringer Ingelheim’s new drug application for zongertinib (BI 1810631) for the treatment of adult patients with ...

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...

Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying China’s CSPC Megalith Biopharmaceutical $15 ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

In pigs receiving anthracyclines, the researchers administered a 20 mg daily dose of the SGLT2 inhibitor empagliflozin, sold as Jardiance by Boehringer Ingelheim. Empagliflozin increases the heart ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks Consensus Estimate of $5.03 per share. Earnings rose 114% year over year.

Revenues in the quarter benefited from a one-time payment of $300 million from partner Boehringer Ingelheim due to an amendment in their collaboration for Jardiance. Higher volumes of drugs like ...